Ocular Therapeutix Annual Revenue, Number of Employees, Growth and Funding


Boston, MA USA
Total Funding:$187.9M
Lead Investor(s):MidCap Financial, Silicon Valley Bank

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Ocular Therapeutix's estimated annual revenue is currently $2M per year.
  • Ocular Therapeutix received $37.5M in venture funding in February 2019.
  • Ocular Therapeutix's estimated revenue per employee is $9,045
  • Ocular Therapeutix's total funding is $187.9M.

Employee Data

  • Ocular Therapeutix has 220 Employees.
  • Ocular Therapeutix grew their employee count by 48% last year.
  • Ocular Therapeutix currently has 8 job openings.

Executive Contacts

David ChesbroDirector, QC
Robert DavisVice President of Market Access
Peter JarrettChief Scientific Officer
Scott CorningSenior Vice President, Commercial
Veronica FaughnanAssociate Director Clinical Operations
Rami ElhayekSenior Director of Research & Discovery
Arthur DriscollVice President Product Development
Scott LeBlancDirector of Finance
Dan BollagChief Strategy Officer
Naymisha PatelVice President, Quality

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix's lead product candidate, DEXTENZA (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals


Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Vita Data Scien...
Agios Pharmaceu...
Adelphi Values
Acer Therapeuti...
Opus Regulatory
Boston Biomedic...
Orbis Clinical
Long Term Pharm...

Ocular Therapeutix News

09/03/2019 - Read This Before Selling Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares

In the last twelve months Ocular Therapeutix insiders were buying shares, but not selling. Their average price was about US$3.67.

09/08/2019 - Ocular Therapeutix, Inc. (OCUL) Skyrockets 3.07% Today: Ride The Wave Of Momentum

If you're on the hunt for stocks to watch today, Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a stock to give close attention to. The company ...

09/03/2019 - Reviewing Ocular Therapeutix Inc. (OCUL)'s and Cyclerion ...

Both Ocular Therapeutix Inc. (NASDAQ:OCUL) and Cyclerion Therapeutics Inc. (NASDAQ:CYCN) are Biotechnology companies, competing ...

Ocular Therapeutix Funding

DateAmountRoundLead InvestorsReference
2013-06-11$UndisclosedUndisclosedBaxter VenturesArticle
2015-06-04$UndisclosedUndisclosedMorgan StanleyArticle
2017-01-25$25.0MUndisclosedCantor Fitzgerald & CoArticle
2018-01-26$37.3MUndisclosedPiper Jaffray & CoArticle
2019-01-02$25.0MUndisclosedMidCap FinancialArticle

Ocular Therapeutix Executive Hires

2016-01-12Jonathan H. TalamoChief Medical OfficerArticle
2016-10-21Andy HurleyChief Commercial OfficerArticle
2017-04-07George MigauskyInterim Chief Financial OfficerArticle
2017-08-02Antony MattessichCEOArticle
2017-08-04Daniel BollagSVP Regulatory Affairs, Pharmacovigilance/QualityArticle
2017-09-11Michael GoldsteinCMOArticle
2017-09-26Donald NotmanChief Financial OfficerArticle
2018-01-09Kevin HanleySVP Technical OperationsArticle
2018-12-07Chad BrinesVice President, SalesArticle

Ocular Therapeutix Staff Cuts

DateNumber of EmployeesLocationReference